tbuckley/cabot-search huggingface dataset:
FRI0284 High prolactin levels are independently associated with damage accrual in systemic lupus erythematosus patients.
Authors: M. F. Ugarte-Gil, R. V. Gamboa-Cardenas, K. Diaz-Deza, M. Medina-Chinchon, F. Zevallos-Miranda, J. M. Cucho-Venegas, R. A. Perich-Campos, J. L. Alfaro-Lozano, A. A. Sanchez-Torres, Z. Rodriguez-Bellido, E. Noriega, H. Torrealva, C. A. Pastor-Asurza
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> High prolactin (PRL) levels have been reported in systemic lupus erythematosus (SLE) patients to be associated with disease activity; they have also been described in patients with chronic diseases like chronic renal failure and chronic liver disease. To our knowledge, an association between disease damage and PRL levels in SLE patients has not been previously evaluated. <h3>Objectives</h3> To determine whether PRL levels are independently associated with disease damage in SLE patients. <h3>Methods</h3> This cross-sectional study was conducted in consecutive SLE patients seen in our Rheumatology Department from January to December 2012. An interview, chart review, physical examination and laboratory tests were performed. SLE was defined using the revised and updated ACR criteria; disease activity was ascertained using the SLEDAI and disease damage with the SLICC/ACR damage index (SDI). Use of steroids was recorded as current dose of prednisone and time of exposure. Chronic liver disease was defined as the presence of cirrhosis or chronic hepatitis. The association between PRL levels and SDI was evaluated using Spearman's correlation. Subsequently, a linear regression model was performed to evaluate the association between PRL levels and SDI, adjusting for age, gender, disease duration, disease activity, thyroid-stimulating hormone (TSH), use of steroids, chronic liver disease and serum creatinine level. <h3>Results</h3> 130 patients were evaluated, 119 (91.5%) were female; their average (SD) age was 42.6 (13.2) years. Disease duration was 7.3 (6.1) years; almost all patients were mestizo. The mean SLEDAI was 5.9 (4.6), the SDI was 0.9 (1.3), 57 (43.8%) patients had at least one point in the SDI. Mean current prednisone dose was 7.8 (4.6) mg/d, and time of exposure to steroids was 7.1 (6.0) years. Mean creatinine level was 1.3 (1.8) mg/dl, 3 (2.3%) patients had chronic liver disease. TSH was 5.2 (10.5) mIU/l, 37 (28.5%) had TSH above upper normal limit. Mean PRL level was 20.0 (14.4) ng/ml, 38 (29.2%) had a PRL level above upper normal limit. In univariate analysis, PRL level was associated with a higher SDI (Rho: 0.29, p: 0.001). In the adjusted model, PRL level remained associated with SDI (β: 0.37, p&lt;0.001). <h3>Conclusions</h3> In our SLE patients, we found a positive association between the prolactin level and SDI, independently of age, gender, disease duration, disease activity, TSH, use of steroids, chronic liver disease and creatinine level. Longitudinal studies are needed to sort out the role of this variable in disease damage in lupus. <b>Disclosure of Interest</b>: None Declared
Reduced Leaflet Motion in Bioprosthetic Aortic Valves — The FDA Perspective
Authors: John C. Laschinger, Changfu Wu, Nicole G. Ibrahim, Jeffrey E. Shuren
Journal: New England Journal of Medicine (2015)

The incidence and mechanism of reduced leaflet motion in bioprosthetic aortic valves and the accompanying risks cannot yet be fully characterized. Whether it is clinically meaningful or merely an advanced-imaging phenomenon demands additional investigation.
PTH-124 Changes In The Indications For Referral Of Adults For Intestinal And Multivisceral Transplantation: Abstract PTH-124 Table 1
Authors: C Rutter, L Sharkey, A Butler, N Russell, S Gabe, N Jamieson, J Woodward, S Duncan, D Bond, J Green, S Middleton
Journal: Gut (2014)

<h3>Introduction</h3> Small bowel transplantation (SBT) was first performed in the UK in Cambridge in 1991. Recipients mow undergo small bowel (SBT), liver and small bowel (LSBT), modified multivisceral (MMVT – small bowel, stomach, pancreas, no liver) and multivisceral (MVT – intestine, stomach, pancreas and liver) transplantation. Cambridge is the only UK centre offering MVT in adults. The main indications for referral to a transplant centre are: Irreversible intestinal failure plus life threatening complications of parenteral nutrition (PN). Extensive surgery requiring partial or complete evisceration. <h3>Methods</h3> Prospective data was collected from all patients who underwent intestinal and multivisceral transplantation at Addenbrooke’s Hospital between 2003 and 2013. All patients are discussed and indications for transplantation agreed prior to listing at NASIT (National Adult Small Intestinal Transplant forum). <h3>Results</h3> 47 transplants were performed on 43 patients; 4 procedures (9%) were re-transplantation for a primary non-functioning graft (2/4) or acute rejection (2/4). The indications for transplant are presented below: Sixteen transplants were performed in 2013 - MVT (57%), SBT (31%), LSB (6%) and MMVT (6%). 50% of these were due to short bowel - arterial ischaemia (50%), Crohn’s (26%), venous ischaemia (12%) and other short bowel (12%). Colon is now routinely included in the graft to aid fluid balance and does not preclude endoscopic surveillance for rejection. <h3>Conclusion</h3> The number of small bowel and multivisceral transplants performed over the last 10 years has increased, and more than doubled in 2013. Short bowel remains the commonest indication for transplantation. Historically this was mainly due to Crohn’s disease however in 2013, it was mainly due to ischaemia; this trend was reflected worldwide. In our cohort, an increase in acute arterial thromboses causing coeliac/mesenteric ischaemia resulted in 3 recipients being listed urgently for MVT. There has also been an increase in the number of patients referred with portal vein thromboses extending into the superior mesenteric vein, precluding liver transplant alone. <h3>Disclosure of Interest</h3> None Declared.
Abstract 4649: Comprehensive isoform expression analysis reveals that EGFR and sEGFR are prognostic determinants of cancer
Authors: Jason A. Wilken, Andre T. Baron, Daniel J. McCormick, Meenakshi Singh, Nita J. Maihle
Journal: Cancer Research (2010)

Abstract In July, 2009 the United States’ Food and Drug Agency (FDA) approved the use of a new biologically-targeted drug called ‘cetuximab’ (Erbitux) for the treatment of patients with advanced colorectal cancer (CRC). Cetuximab is a chimeric antibody directed against the extracellular domain of the epidermal growth factor receptor (EGFR). Paradoxically, EGFR expression, as it is currently measured by commercially available assays, has not been useful for predicting who will respond to cetuximab. We propose that one problem with these assays is their inability to measure EGFR and soluble EGFR (sEGFR) isoforms independently. We previously have documented the expression of an sEGFR isoform in human tissues (1), and have generated antibodies directed against a 31-mer peptide (residues 604-634) located within the unique 78 amino acid carboxy-terminal sequence of sEGFR (2). Interestingly, this anti-sEGFR antibody recognizes a second protein of ∼140-kDa (p140), which we have identified as human α5-integrin. Biochemical and mass spectrometry analyses show that a short region in the calf domain of α5-integrin shares sequence identity with the 31-mer sEGFR peptide. We have used this 31-mer antibody with an antibody directed against the intracellular domain of full-length EGFR to develop a novel EGFR vs. sEGFR/α5-integrin expression assay. This assay demonstrates that sEGFR/α5-integrin is co-expressed with EGFR in normal as well as malignant tissues, including in a number of carcinoma-derived cell lines. We also observe that high expression of EGFR and sEGFR/α5-integrin in a large cohort of ovarian cancer patients defines a strong adverse prognostic determinant of survival. These results implicate EGFR, sEGFR, and integrins as cancer biomarkers and demonstrate the critical importance of independently assessing both full-length and soluble EGFR isoforms in prognostic EGFR expression assays. *–JAW and ATB contributed equally to this study (1). Reiter et al. (2001) Genomics. 71(1):1-20 (2). Christensen et al. (2002) Hybrid Hybridomics. 21(3):183-9 Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 4649.
B-cell–specific conditional expression of Myd88p.L252P leads to the development of diffuse large B-cell lymphoma in mice
Authors: Gero Knittel, Paul Liedgens, Darya Korovkina, Jens M. Seeger, Yussor Al-Baldawi, Mona Al-Maarri, Christian Fritz, Katerina Vlantis, Svetlana Bezhanova, Andreas H. Scheel, Olaf-Oliver Wolz, Maurice Reimann, Peter Möller, Cristina López, Matthias Schlesner, Philipp Lohneis, Alexander N. R. Weber, Lorenz Trümper, Louis M. Staudt, Monika Ortmann, Manolis Pasparakis, Reiner Siebert, Clemens A. Schmitt, Andreas R. Klatt, F. Thomas Wunderlich, Stephan C. Schäfer, Thorsten Persigehl, Manuel Montesinos-Rongen, Margarete Odenthal, Reinhard Büttner, Lukas P. Frenzel, Hamid Kashkar, H. Christian Reinhardt
Journal: Blood (2016)
Case 4-2006
Authors: Jonathan Kay, David S. Finn, James R. Stone
Journal: New England Journal of Medicine (2006)

A 79-year-old woman had abrupt onset of pain in the shoulders, neck, and back two days after beginning treatment with ezetimibe. These symptoms persisted, and weakness developed despite discontinuing ezetimibe. The erythrocyte sedimentation rate was 90 mm per hour. Prednisone (20 mg daily) led to improvement in the muscle pain and weakness, but dyspnea and hoarseness developed, and she was admitted to the hospital. A diagnostic procedure was performed.
Abstract 5678: Kavalactone yangonin induces autophagy, inhibits TSC-mediated translation initiation and acts synergistically with a kava chalcone flavokawain A on growth inhibition in bladder cancer UMUC-3 cells
Authors: Zhongbo Liu, Xuesen Li, Anna Simoneau, Xiaolin Zi
Journal: Cancer Research (2010)

Abstract Autophagy is a tightly regulated lysosomal self-digestion process that has been shown to suppress primary tumor formation. However, the mechanisms and potential usefulness of autophagy induction in cancer prevention remain controversial and largely unknown. To facilitate the study of the potential of autophagy induction as a mechanism for bladder cancer prevention, we have established a bladder cancer cell line with a stably over-expressed EGFP-LC3 gene (a hallmark gene for autophagy). Using this cell line, we screened out kavalactones yangonin and dehydrokawain as strong autophagy inducers in bladder cancer cells, but not the previously defined apoptosis inducers flavokawains also found in kava root extracts. Yangonin treatment at concentrations of 1.25 to 50 μg/ml for eight hours significantly increases the percentage of EGFP-LC3 cells with punctuate EGFP-LC3 fluorescence up to 80%. The induction of autophagy by yangonin treatment was further confirmed by electron microscopy observation of increased autolysosome formation and by western blotting analysis of LC3-II cleavage. The effect of yangonin on autophagy induction corresponds to its anchorage-dependent and independent growth inhibitory effect in a dose and time dependent manner in UM-UC-3 cells. Similarly, yangonin also induces autophagy and inhibits cell growth in another bladder cancer cell line T24. Further study demonstrated that yangonin is less effective in reducing the cell viability of the primary mouse embryo fibroblasts tuberous sclerosis-1 knockout (MEF TSC1−/−) than that of wild-type cells (MEF TSC1+/+) cells. This result suggested that TSC1 may be, at least in part, required for the growth inhibitory effect of yangonin. Immunoprecipitation experiments showed an increased formation of the TSC1/TSC2 immunocomplex after yangonin treatment in UMUC-3 cells. In addition, yangonin treatment of UMUC-3 cells resulted in a decrease in phosphorylation of mTOR and 4E-BP1 with subsequent increased binding of 4E-BP1 to m7GTP, which is responsible for stoppage of translational initiation. Interestingly, yangonin in combination with flavokawain A, an apoptosis inducer, synergistically inhibits the growth of UMUC-3 cells. Taken together, our results may suggest a novel strategy for bladder cancer chemoprevention through combination of autophagy and apoptosis inducers, yangonin and flavokawain A. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 5678.
Tritiated Digoxin XVIII
Authors: W. T. DUNGAN, J. E. DOHERTY, C. HARVEY, F. CHAR, G. V. DALRYMPLE
Journal: Circulation (1972)

Tritiated digoxin turnover studies were performed in nine children aged 4 days to 7 years. Mean serum turnover time was 32.5 (range 18-48) hours, and the 3-day urine and stool excretion was 55% of the total dose administered. These findings are quite similar to those observed in adults and indicate that the larger doses of digoxin required for digitalization in infants are not accompanied by increased metabolism or excretion but by increased blood levels and presumably increased tissue concentrations of the glycoside.
Abstract P3-03-01: 3D mapping of total choline in human breast cancer using high-speed MR spectroscopic imaging at 3T: initial experience during neoadjuvant therapy
Authors: S Posse, T Zhang, M Royce, Z Dayao, S Lopez, L Sillerud, L Casey, S Eberhardt, L Lomo, A Rajput, J Russell, S-j Lee, P Bolan
Journal: Cancer Research (2012)

Abstract OBJECTIVE: To assess the feasibility of quantitative high-speed MR spectroscopic imaging (MRSI) of total Choline (tCho) as an adjunct to dynamic-contrast enhanced MRI to improve lesion characterization and monitor treatment response in patients undergoing neoadjuvant chemotherapy (NAC). METHODS: Twelve patients with infiltrating ductal carcinoma (Table 1) were studied using a clinical 3T MR scanner (Siemens, Erlangen, Germany) equipped with 8- and 16-channel breast array (Hologic Inc., Bedford, MA). Four patients were studied before NAC. Four patients were studied once during NAC. Two patients were studied before and within 2–7 days of treatment initiation. One of these patients participated in an additional scan after 5 months of treatment. Two additional patients were studied at 3 time points during NAC. Measurements were performed using PRESS prelocalized 3D Proton-Echo-Planar-Spectroscopic-Imaging (PEPSI) using TR/TE=2000ms/135ms, matrix size up to 32×16×8, voxel size = 1cc, and total acquisition time of 10 minutes (including water reference scan). Additional data were collected at TE 60 ms to enhance sensitivity for detecting tCho and J-coupled resonances. TE-averaging (8 steps, DTE: 2.5 ms) was employed to minimize gradient sideband artifacts. Quantification of tCho in reference to tissue water was performed using spectral fitting and relaxation correction. RESULTS: Strongly elevated tCho with maximum concentration up to 5.3 mmol/kg was measured in 9 patients with enhancing lesions larger than 2 cc volume (Table 2). Decreases in tCho were measured in all four patients who were followed during neoadjuvant chemotherapy. Decreases in tCho were measurable during the first week of neoadjuvant treatment in responders, consistent with previous studies. Our preliminary data also indicate that the combination of concentration and spatial extent of detectable tCho may be the most sensitive marker of treatment response. CONCLUSION: This study demonstrates feasibility of quantitatively mapping tCho in invasive breast carcinoma using high-speed MRSI. The long-term goals are to utilize high-speed MRSI as an early predictor of treatment failure in women undergoing neoadjuvant therapy (i.e. chemotherapy, endocrine therapy or biologic therapy) for breast cancer and to develop an improved screening protocol for high-risk patients. Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P3-03-01.
AB0933 Retroperitoneal Fibrosis, Igg4-Related Diseases and Cardiovascular Fibrosclerosis
Authors: O. Karadag, U. Kalyoncu, L. Kilic, O. Helvaci, Y.Z. Sener, A. Akdogan, T. Hazirolan, S. Apras Bilgen, I. Ertenli, S. Kiraz
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> The diagnosis of cardiovascular fibrosclerosis (CF), become more feasible parallel to technologic improvements in imaging modalities. CF may manifest as idiopathic retroperitoneal fibrosis (RPF), inflammatory aortic aneurysm (IAA), inflammatory periarteritis, and inflammatory pericarditis.<sup>1</sup> A certain fraction, but not all, of CF may have a link with immunoglobulin-G4 (IgG4)-related sclerosing disease (IgG4-SD). Most of the data depends on case reports/series. <h3>Objectives</h3> This study is aimed to investigate the experience our rheumatology clinic and increase the awareness of physicians about this concept. <h3>Methods</h3> Our database was screened regarding manifestations of CF. Demographic, clinical characteristics and imaging studies in addition to IgG4 levels were recorded. Patients fulfilling criterias of any connective tissue diseases and/or vasculitis were excluded. Also the patients are divided into two groups a (IgG4 elevated or normal range). Vascular and extravascular involvement characteristics of patients are compared. <h3>Results</h3> Totally 16 patients (Male/Female: 10/6) were included into the study. Mean age was 53.6±9.2 years. Most of the patients had RPF. Distribution of involvements was shown in Table 1. Serum IgG4 levels were measured in all of the patients. Nine (56.3%) of patients had elevated IgG4 levels. Patients with elevated IgG4 levels had more systemic involvements (periorbital and lymphadenopathy involvements were statistically significant-Table). In all of the periarteritis cases, coronary artery had been involved. One of the patients with coronary arteritis had normal IgG4 level. Even though pulse corticosteroid therapy, this patient had coronary artery bypass graft because of resistant angina pectoris and elevated cardiac enzymes (Fig. 1). <h3>Conclusions</h3> Cardiovascular fibrosclerosis is an emerging concept in rheumatology. Patients with RPF should be evaluated about IgG4 related diseases. Although patients with elevated IgG4 levels seems to have more systemic involvement, patients with normal ıgG4 level may have severe disease course. Pathologic specimen analysis of these patients in view of IgG4 related diseases could enlarge understandings of CF. <h3>References</h3> Ishikaza N, Sakomoto A, Imai A et al. Multifocal fibrosclerosis and Ig-G4 related disease involving the cardiovascular system <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.3715
Pseudoaneurysm after Transradial Coronary Angiography
Authors: Juan C Moy Petersen, Juan J Vidal Insua
Journal: New England Journal of Medicine (2015)

An 81-year-old woman presented with a large, painless, pulsatile swelling of the right wrist that had progressively increased in size. The patient had undergone transradial coronary angiography 1 month earlier. A diagnosis of radial pseudoaneurysm was confirmed on ultrasonography.
PMO-104 The use of faecal elastase in a district general hospital
Authors: E Tash, J Subhani, D Lindo, D Gertner, M Joy, R Carrigan, T Everitt, P Munuswamy
Journal: Gut (2012)

<h3>Introduction</h3> Faecal elastase 1 (FE) is a proteolytic enzyme secreted by the acinar cells of the pancreas. Its determination is a highly sensitive and specific tubeless pancreatic function test. The 2003 BSG guidelines were compiled to minimise investigations and maximise positive diagnoses for patients with diarrhoea lasting more than 4 weeks.<sup>1</sup> We analysed the appropriate use of the faecal elastase test and its correlation with symptoms in a large district general hospital. <h3>Methods</h3> This retrospective study included all patients who had a FE requested from April 2009 to March 2010. Data were analysed for indication, symptoms, outcome of the test, follow-up, other investigations and the use of creon. <h3>Results</h3> Over a period of 1 year, 121 patients had a FE requested. Patient notes and laboratory information was only available for a total of 101 patients. Data were collected from these notes for further analysis. 19 patients (19%) had pancreatic insufficiency with low FE levels (ranging &lt;15–144). 82 patients had normal FE levels (&gt;500). In patients with a low FE levels, 12 patients had diarrhoea (63%), steatorrhoea (21%), abdominal pain (26%), weight loss (47%), alcohol history (15%), history of pancreatitis in (53%) and none of these patients had abdominal distention, flatulence or offensive stools. 58% in the low FE group had treatment with creon. A logistic regression analysis was performed on three symptoms; diarrhoea, steatorrhoea and previous history of pancreatitis. History of pancreatitis was statistically significant with an OR of 10.21, for faecal elastase insufficiency. <h3>Conclusion</h3> In our study group we found that a previous history of pancreatitis was a strong predictor of a low faecal elastase. Though statistically not significant, patients with diarrhoea, steatorrhoea and weight loss, do benefit from FE testing. <h3>Competing interests</h3> None declared. <h3>Reference</h3> 1. <b>Thomas PD</b>, <i>et al.</i> Guidelines for the investigation of chronic diarrhoea. 2nd edn. <i>Gut</i> 2003;<b>52</b>(Suppl V):v1–5.
Proton Beam Therapy—Cost vs. Benefit
Authors: Florence S. Antoine
Journal: JNCI Journal of the National Cancer Institute (1989)

Journal Article Proton Beam Therapy—Cost vs. Benefit Get access Florence S. Antoine Florence S. Antoine Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 81, Issue 8, 19 April 1989, Pages 559–562, https://doi.org/10.1093/jnci/81.8.559 Published: 03 January 1990
EU Cancer Code Tuned-Up, Targets GPs and the Public
Authors: T. Reynolds
Journal: JNCI Journal of the National Cancer Institute (1995)

Journal Article EU Cancer Code Tuned-Up, Targets GPs and the Public Get access Tom Reynolds Tom Reynolds Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 87, Issue 24, 20 December 1995, Pages 1832–1833, https://doi.org/10.1093/jnci/87.24.1832-a Published: 20 December 1995